Scinai Immunotherapeutics Ltd (SCNI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.164x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.29 Million) by net assets ($7.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scinai Immunotherapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scinai Immunotherapeutics Ltd total liabilities for a breakdown of total debt and financial obligations.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
M&G Credit Income Investment Trust PLC
LSE:MGCI
|
-0.061x |
|
APOLLO GROUP-A
F:APO
|
0.076x |
|
Yowie Group Ltd
AU:YOW
|
-0.091x |
|
GOLCAP RESOURCES CORP
F:2SO0
|
-0.030x |
|
BuilderSmart Public Company Limited
BK:BSM
|
0.083x |
|
Blockchaink2 Corp
V:BITK
|
0.024x |
|
N2OFF Inc
NASDAQ:NITO
|
-0.124x |
|
Lord Resources Ltd
AU:LRD
|
-0.317x |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Scinai Immunotherapeutics Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -252.16% |
| 2020-12-31 | $-4.54 Million | $-22.57 Million | 4.970x | +319.55% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more